Please try another search
Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
James Irvin Healy | 59 | 2023 | Independent Director |
David J. Julius | - | - | Co-Chair of Scientific Advisory Board |
David W.C. MacMillan | - | - | Co-Chair of Scientific Advisory Board |
Wendy Young | - | 2023 | Member of Scientific Advisory Board |
John M. Maraganore | 62 | 2024 | Independent Director |
Allan Basbaum | - | - | Member of Scientific Advisory Board |
Jeffrey L. Noebels | - | - | Member of Scientific Advisory Board |
Jeffrey K. Tong | 48 | 2022 | Independent Director |
Reid M. Huber | 52 | 2022 | Director |
David E. Clapham | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review